Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure.

RATIONALE Fluoroquinolones are the most commonly prescribed antibiotic class in the United States. They have the potential to become first-line antituberculosis therapy, but the effect of fluoroquinolone use on fluoroquinolone resistance in Mycobacterium tuberculosis is not well characterized. OBJECTIVES To determine the prevalence of and risk factors for fluoroquinolone-resistant tuberculosis in a large United States population. METHODS We identified all people with culture-confirmed tuberculosis enrolled in TennCare (Medicaid) and reported to the Tennessee Department of Health from January 2002 to December 2006. People with fluoroquinolone-resistant M. tuberculosis isolates (cases) were compared with those with susceptible isolates (control subjects). Fluoroquinolone resistance was determined by agar proportion using ofloxacin 2 microg/ml. Outpatient fluoroquinolone exposure in the 12 months before tuberculosis diagnosis was ascertained from TennCare pharmacy data. MEASUREMENTS AND MAIN RESULTS Of 640 study patients, 116 (18%) had fluoroquinolone exposure in the 12 months before diagnosis, and 16 (2.5%; 95% confidence interval [CI], 1.4-4.0%) M. tuberculosis isolates were fluoroquinolone resistant. Among the 54 patients with more than 10 days of fluoroquinolone exposure, 7 (13%) had fluoroquinolone resistance. In multivariable logistic regression analyses using propensity score to control for age, sex, race, HIV serostatus, and site of disease, more than 10 days of fluoroquinolone exposure before tuberculosis diagnosis was associated with fluoroquinolone resistance (odds ratio 7.0; 95% CI, 2.3-20.6; P = 0.001). Fluoroquinolone exposure for more than 10 days that occurred more than 60 days before tuberculosis diagnosis was associated with the highest risk of resistance (20.8%; odds ratio 17.0; 95% CI, 5.1-56.8; P < 0.001 compared with no exposure). CONCLUSIONS Overall, fluoroquinolone resistance was relatively low. However, receipt of fluoroquinolones for more than 10 days, particularly more than 60 days before tuberculosis diagnosis, was associated with a high risk of fluoroquinolone-resistant tuberculosis.

[1]  R. Wallace,,et al.  Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes , 2011 .

[2]  D. Mitchison,et al.  A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  T. Sterling,et al.  Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. , 2007, Archives of internal medicine.

[4]  P. de Rijk,et al.  Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. , 2007, Journal of Antimicrobial Chemotherapy.

[5]  Pan‐Chyr Yang,et al.  Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. , 2007, The Journal of antimicrobial chemotherapy.

[6]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  T. Shim,et al.  Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  R. Stafford,et al.  Fluoroquinolone prescribing in the United States: 1995 to 2002. , 2005, The American journal of medicine.

[9]  B. Metchock,et al.  Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  J. T. Crawford,et al.  Evaluation of a Two-Step Approach for Large-Scale, Prospective Genotyping of Mycobacterium tuberculosis Isolates in the United States , 2005, Journal of Clinical Microbiology.

[11]  K. Dooley,et al.  Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. , 2003, Clinical Infectious Diseases.

[12]  S. Dorman,et al.  The rapid development of fluoroquinolone resistance in M. tuberculosis. , 2003, The New England journal of medicine.

[13]  Charles L Daley,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[14]  S. Hoffner,et al.  In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. , 1997, The Journal of antimicrobial chemotherapy.

[15]  L. Young,et al.  In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis. , 1987, The Journal of antimicrobial chemotherapy.

[16]  K. Citron.  Trends in tuberculosis. , 1984, Postgraduate medical journal.

[17]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.